| 摘要 |
Disclosed are crystalline salts of 2-[4-((1S,2S)-2-{ [(2S)-2-methylpyrrolidin-1-yl]methyl} cyclopropyl)phenyl]pyridazin-3(2H)-one, wherein the salts include crystalline 2-{ 4-[(1S,2S)-2-{ [(S)-2-methyl-pyrrolidin-1-yl]methyl)-cyclopropyl]-phenyl} -2Hpyridazin-3-one L-bitartrate monohydrate, crystalline 2-{ 4-[(1S,2S)-2-{ [(S)-2-methyl-pyrrolidin-1-yl]methyl)-cyclopropyl]-phenyl} -2Hpyridazin-3-one L-bitartrate anhydrate, crystalline 2-{ 4-[(1S,2S)-2-{ [(S)-2-methyl-pyrrolidin-1-yl]methyl)-cyclopropyl]-phenyl} -2Hpyridazin-3-one D-bitartrate dihydrate and crystalline 2-{ 4-[(1S,2S)-2-{ [(S)-2-methyl-pyrrolidin-1-yl]methyl)-cyclopropyl]-phenyl} -2Hpyridazin-3-one D-bitartrate anhydrate. These compounds are suitable for selectively modulating histamine-3 (H3) receptor activity and are particularly useful for treating and preventing a condition or disorder affecting attention-deficit hyperactivity, Alzheimer's disease, dementia, a condition or disorder affecting schizophrenia, cognitive deficits of schizophrenia, a condition or disorder affecting narcolepsy, sleep disorders, allergic rhinitis, asthma, or obesity. |
